Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours
Source abstract
Abstract
M cell cycle arrest, apoptosis, mitochondrial membrane potential disruption and ROS production was exhibited by PTX-SEDDS in comparison to Taxol. Up-regulation of Bax, p21, cleaved-caspase 3, -caspase 9 and down-regulation of Bcl2 and survivin suggested apoptosis via intrinsic pathways. Pharmacokinetic study showed approximately 4-folds higher oral bioavailability of PTX-SEDDS than Taxol. Significant reduction in tumour volume and weight was observed in syngeneic mammary tumour in SD rats. Tumour histopathology and TUNEL assay showed apoptosis in tumour tissue. PTX-SEDDS caused low lung metastasis, and was safe and stable. Conclusively, PTX-SEDDS could be suitable option for oral delivery of PTX.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · 3D Printing in Biomedical Research · Innovative Microfluidic and Catalytic Techniques Innovation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute
Endocrinology Division, CSIR-Central Drug Research Institute
Funding
Department of Biotechnology, Government of India
References (28)
Show source-provided references
1. 10.1016/S0378-5173(98)00188-410.1016/S0378-5173(98)00188-4 ↗
2. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc. 2002;23:205–208.
3. 10.1016/j.ijpharm.2005.01.01110.1016/j.ijpharm.2005.01.011 ↗
4. Terwogt JMM, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clinical Cancer Research 1999;5:3379–3384.
5. 10.1021/mp060121r10.1021/mp060121r ↗
6. 10.1016/S0168-3659(02)00025-110.1016/S0168-3659(02)00025-1 ↗
7. 10.1016/j.ejps.2013.02.00610.1016/j.ejps.2013.02.006 ↗
8. 10.1016/j.jconrel.2014.10.01010.1016/j.jconrel.2014.10.010 ↗
9. 10.1016/j.ijpharm.2009.08.03510.1016/j.ijpharm.2009.08.035 ↗
10. 10.3109/10837450.2013.79517010.3109/10837450.2013.795170 ↗
11. Yang XH, Sladek TL, Liu X, et al. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 2001;61:348–354.
12. 10.1016/j.bbagen.2016.07.00110.1016/j.bbagen.2016.07.001 ↗
13. 10.1039/C6RA02663J10.1039/C6RA02663J ↗
14. 10.2165/00003088-199630030-0000110.2165/00003088-199630030-00001 ↗
15. 10.1016/0378-5173(94)00222-Q10.1016/0378-5173(94)00222-Q ↗
16. 10.1016/j.carbpol.2013.03.07610.1016/j.carbpol.2013.03.076 ↗
17. 10.1016/j.jconrel.2015.06.01910.1016/j.jconrel.2015.06.019 ↗
18. 10.1016/j.ijpharm.2014.05.03910.1016/j.ijpharm.2014.05.039 ↗
19. 10.1091/mbc.e14-04-091610.1091/mbc.e14-04-0916 ↗
20. 10.1038/nrc96810.1038/nrc968 ↗
21. 10.1016/j.biomaterials.2012.08.00710.1016/j.biomaterials.2012.08.007 ↗
22. 10.1016/j.ctrv.2008.04.00310.1016/j.ctrv.2008.04.003 ↗
23. 10.1016/j.biomaterials.2012.03.04610.1016/j.biomaterials.2012.03.046 ↗
24. 10.1016/j.bcp.2014.02.00310.1016/j.bcp.2014.02.003 ↗
25. 10.1054/bjoc.2001.211810.1054/bjoc.2001.2118 ↗
26. 10.1007/s10616-008-9173-910.1007/s10616-008-9173-9 ↗
27. 10.1016/j.physbeh.2013.05.02610.1016/j.physbeh.2013.05.026 ↗
28. 10.1016/j.jconrel.2014.03.00910.1016/j.jconrel.2014.03.009 ↗